QIAGEN Gathers TB Experts Amid Rising Disease Burden and Funding Pressures
Event summary
- QIAGEN hosts the Global TB Clinical and Educational Summit from October 13-16, 2026, addressing persistent TB challenges.
- WHO reports 10.7 million TB cases and 1.2 million deaths in 2024, with funding cuts threatening progress.
- QIAGEN's QuantiFERON-TB Gold Plus test has sold over 160 million units globally.
- Summit focuses on TB prevention, screening, and care, with discussions on funding cuts and vulnerable populations.
The big picture
QIAGEN's summit underscores the tension between persistent TB cases and shrinking global health funding. As a leader in diagnostic solutions, QIAGEN is positioning itself as a critical partner in sustaining TB control efforts. The event highlights the company's strategic focus on education and testing innovation amid broader industry challenges in infectious disease management.
What we're watching
- Funding Pressures
- Whether WHO's warnings about donor funding cuts will accelerate or derail TB prevention efforts.
- Diagnostic Adoption
- The pace at which QIAGEN's QuantiFERON-TB Gold Plus test will expand in high-risk populations.
- Strategic Positioning
- How QIAGEN leverages this summit to reinforce its leadership in TB diagnostics amid rising disease cases.
Related topics
